FIELD: medicine.
SUBSTANCE: invention refers to medicine, more specifically to pharmacology, haematology and oncology. Disclosed is use of a protein kinase A (PKA) activator as a haemoprotective agent, effective when administered in vivo with respect to erythro- and granulomonocytopoiesis.
EFFECT: technical result consists in the implementation of the PKA activators by cAMP analogues 8-Cl-cAMP and 8-Br-cAMP, which corrected the changes in the number of erythroid cells and monocytes in the cytostatic myosuppressive cyclophosphan mice.
1 cl, 3 tbl, 1 ex
Title | Year | Author | Number |
---|---|---|---|
HEMOPROTECTIVE AGENT | 2019 |
|
RU2725135C1 |
HEMOSTIMULATING AGENT | 2017 |
|
RU2647833C1 |
HAEMOSTIMULATING AGENT | 2013 |
|
RU2535021C1 |
HEMOSTIMULATING AGENT | 2013 |
|
RU2514648C1 |
HEMOSTIMULATING MEDICATION | 2012 |
|
RU2505308C1 |
METHOD FOR STIMULATING MYELOGENESIS | 2010 |
|
RU2442589C1 |
METHOD OF MYELOPOIESIS STIMULATION | 2007 |
|
RU2336899C1 |
METHOD OF MYELOPOIESIS STIMULATION | 2008 |
|
RU2366452C1 |
METHOD FOR PREPARING CELL TRANSPLANTATION MATERIAL IN MYELOSUPPRESSION | 2008 |
|
RU2392947C1 |
METHOD OF DETERMINING EFFICACY OF HAEMOSTIMULATORS IN CYTOSTATIC MYELOSUPPRESSION | 2009 |
|
RU2421720C2 |
Authors
Dates
2019-08-05—Published
2018-07-02—Filed